SCLX
Scilex Holding Company
NASDAQ · Healthcare · Drug Manufacturers - General · US
$5.42
+2.56%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
58.0x
EV/EBITDA
−0.4x
Market Cap
$45.99M
MomentumView details →
1D Return
+2.56%
YTD Return
−54.30%
RSI (14)
38.7
ValuationView details →
P/E (Fwd)
58.0x
EV/EBITDA
−0.4x
Market Cap
$45.99M
RSI (14)
38.7
MomentumView details →
1D Return
+2.56%
YTD Return
−54.30%
SummaryUpdated Jun 1, 2026
Scilex Holding Company (NASDAQ:SCLX) is a biopharmaceutical company founded in 2016 and publicly traded since March 2021. Based in Palo Alto, California, the company operates as a subsidiary of Sorrento Therapeutics and focuses on developing and commercializing non-opioid pain management solutions. Scilex addresses the critical healthcare challenge of treating acute and chronic pain without contributing to the opioid crisis that has plagued the United States for decades.
Similar companies
Latest newsMore news →
DataMeds AI announced the pending transaction with Datavault AI, EOS Technology Holdings, Scilex Holdings and HealthBridge Associates to consolidate intellectual properties and deliver the 'Health Lives Here' consumer app in partnership with NFL Alumni Health.18d agoScilex loan was substantially repaid to Oramed Pharmaceuticals.71d agoScilex Holding Company set June 15, 2026 as the payment date for its previously announced dividend of Semnur Pharmaceuticals common stock to holders of Scilex common stock and other eligible equity securities.92d ago